Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Publication Name: Annals of Surgical Oncology

Author(s): Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD.

PURPOSE: The purpose of the NBRST study is to compare a multigene classifier to conventional immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) subtyping to predict chemosensitivity as defined by pathological complete response (pCR) or endocrine sensitivity as defined by partial response. … Continued

Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups

Publication Name: Cancer Research

Author(s): Massimo Cristofanilli, Karen Kaul, Mary Turk, JoEllen Weaver, Jelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Katharine Yao

This retrospective study showed that Molecular Subtyping of early breast cancers using Mammaprint and BluePrint leads to reclassification of 25% (51/208) of tumors with potential therapeutic and prognostic implications: – 39% of clinical HER-2 disease should have been treated with … Continued